Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ABOS

Acumen Pharmaceuticals, Inc.

Healthcare | Biotechnology
$2.29 -0.05 (-2.14%) as of 2026-07-14 21:18 UTC
Volume413.6K

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a biotechnology company trading at $2.29 (−2.1% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 21:18 UTC.

52-Week Range
Low $1.05High $3.60

What Acumen Pharmaceuticals, Inc. does

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease by targeting soluble amyloid-beta oligomers, which researchers believe are a primary cause of the disease. The company's lead drug candidate, sabirnetug, is a monoclonal antibody currently being tested in the Phase 2 ALTITUDE-AD trial, which is expected to report results in late 2026. In the prior Phase 1 INTERCEPT-AD trial, sabirnetug demonstrated safety and evidence of working against Alzheimer's pathology in patients with early disease.

Summarized from Acumen Pharmaceuticals, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$2.29
Change (1D)-0.05 (-2.14%)
Volume413.6K shares
52-week range$1.05 – $3.60
Returns
52-week return+118.1%
Price Chart
52-Week Range
Low $1.05High $3.60
Interactive chart available in terminalLive price charts with full OHLCV data, volume overlay, and technical indicators.
Open ABOS in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-06-17
  • 2026-06-17Porter DerrellSELL-6,460$15.1K
  • 2026-06-17Porter DerrellM6,460$6.9K
  • 2026-06-17Porter DerrellSELL-12,800$29.8K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • RA CAPITAL MANAGEMENT, L.P.20,992,669$49.54M+40.6%
  • Sands Capital Alternatives, LLC3,720,105$8.78M+8.9%
  • Alyeska Investment Group, L.P.2,454,754$5.78M+161.2%
View QoQ ownership changes →
Company news View all →
No qualifying company news in the archive. Full tape in the platform →
Questions this page answers

What does Acumen Pharmaceuticals, Inc. do?

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease by targeting soluble amyloid-beta oligomers, which researchers believe are a primary cause of the disease.

What is ABOS's valuation?

ABOS trades at $2.29, as of 2026-07-14.

When did ABOS last file with the SEC?

Acumen Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-16. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 21:18 UTC. This page is also available as JSON at /api/data?ticker=ABOS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ABOS and 3,500+ tickers.

Create a free account — keep ABOS
For your agent
GET /api/data?ticker=ABOS

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt